In a report released today, Peter Welford from Jefferies maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price target of $52.50. The company’s shares closed last Friday at $45.07.
According to TipRanks, Welford is a 4-star analyst with an average return of 4.4% and a 53.57% success rate. Welford covers the Healthcare sector, focusing on stocks such as Roche Holding AG, GlaxoSmithKline, and Novo Nordisk.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GlaxoSmithKline with a $49.25 average price target.
GSK market cap is currently $91.88B and has a P/E ratio of 16.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GlaxoSmithKline (GSK) Company Description:
Founded in 1715 and headquartered in Brentford, U.K., GlaxoSmithKline Plc is a global healthcare company which develops and manufactures pharmaceutical medicines in therapeutic areas, vaccines and consumer healthcare products in wellness, oral health, nutrition, and skin health categories.
